We are live on ! Find out more
GKIM

GW&K Investment Management Portfolio holdings

AUM $11.3B
1-Year Est. Return 31.98%
This Fund
S&P 500
This Quarter Est. Return
+8.94%
1 Year Est. Return
+31.98%
3 Year Est. Return
+79.76%
5 Year Est. Return
+101.81%
10 Year Est. Return
+512.72%
AUM
$7.49B
AUM Growth
+$381M
Cap. Flow
-$168M
Cap. Flow %
-2.25%
Top 10 Hldgs %
11.97%
Holding
386
New
15
Increased
64
Reduced
279
Closed
9

Sector Composition

Rank Sector Weight
1 Industrials 16.68%
2 Technology 15.03%
3 Healthcare 13.83%
4 Financials 13.24%
5 Consumer Discretionary 13.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MMYT icon
201
MakeMyTrip
MMYT
$5.8B
$11.8M 0.16%
517,210
+46,631
+10% +$1.13M
WAAS
202
DELISTED
AquaVenture Holdings Limited
WAAS
$11.6M 0.15%
427,800
-9,176
-2% -$195K
APAM icon
203
Artisan Partners
APAM
$3.08B
$11.3M 0.15%
351,023
-12,351
-3% -$357K
MIME
204
DELISTED
Mimecast Limited
MIME
$10.8M 0.14%
249,694
-11,306
-4% -$470K
FOXF icon
205
Fox Factory Holding Corp
FOXF
$913M
$10.5M 0.14%
151,347
-6,847
-4% -$442K
WWD icon
206
Woodward
WWD
$21.1B
$10.5M 0.14%
88,478
-3,964
-4% -$447K
FRC
207
DELISTED
First Republic Bank
FRC
$10.3M 0.14%
88,019
-1,590
-2% -$172K
GSHD icon
208
Goosehead Insurance
GSHD
$2.34B
$10.2M 0.14%
240,665
-35,804
-13% -$1.58M
CPA icon
209
Copa Holdings
CPA
$5.51B
$10.1M 0.14%
93,565
-56,476
-38% -$5.89M
TMX
210
DELISTED
Terminix Global Holdings, Inc.
TMX
$9.91M 0.13%
256,321
+42,072
+20% +$1.79M
QCOM icon
211
Qualcomm
QCOM
$170B
$9.28M 0.12%
105,181
+38,611
+58% +$3.23M
SHYF
212
DELISTED
The Shyft Group
SHYF
$9.12M 0.12%
504,246
-20,676
-4% -$345K
AIMT
213
DELISTED
Aimmune Therapeutics
AIMT
$8.88M 0.12%
265,402
-11,662
-4% -$326K
GBT
214
DELISTED
Global Blood Therapeutics, Inc.
GBT
$8.7M 0.12%
109,466
-35,048
-24% -$2.08M
ICLR icon
215
Icon
ICLR
$12.8B
$8.35M 0.11%
48,467
-2,322
-5% -$358K
INFY icon
216
Infosys
INFY
$51.2B
$8.03M 0.11%
777,825
-79,970
-9% -$805K
BHVN
217
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$7.62M 0.1%
140,046
-6,330
-4% -$313K
PYPL icon
218
PayPal
PYPL
$50.5B
$7.56M 0.1%
69,849
-5,767
-8% -$601K
UFPT icon
219
UFP Technologies
UFPT
$2.5B
$7.24M 0.1%
145,878
-9,350
-6% -$408K
HZNP
220
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$7.05M 0.09%
+194,728
New +$5.97M
ZGNX
221
DELISTED
Zogenix, Inc.
ZGNX
$7.04M 0.09%
135,137
-11,002
-8% -$504K
PAGS icon
222
PagSeguro Digital
PAGS
$2.51B
$7.03M 0.09%
205,910
-33,025
-14% -$1.19M
CRL icon
223
Charles River Laboratories
CRL
$13.4B
$7.01M 0.09%
45,912
-3,030
-6% -$420K
CBZ icon
224
CBIZ
CBZ
$2.96B
$6.8M 0.09%
252,097
-6,765
-3% -$176K
CSL icon
225
Carlisle Companies
CSL
$15.6B
$6.61M 0.09%
40,841
-2,757
-6% -$425K

Similar funds

GW&K Investment Management's Q4 2019 Portfolio in Review

As of Q4 2019, GW&K Investment Management held 386 positions worth $7.49B, up 5.4% from $7.11B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

GW&K Investment Management's Q4 2019 filing shows 15 new, 64 increased, 279 reduced and 9 closed positions. Its largest new stake was Veracyte: 1,020,082 shares worth $28.5M. The largest sale was Cambrex Corporation, an estimated $27.1M.

By sector, the portfolio is most concentrated in Industrials at 17% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.

  • GW&K Investment Management's largest Q4 2019 buy was Veracyte: 1,020,082 shares worth $28.5M.
  • GW&K Investment Management added most to Ollie's Bargain Outlet in Q4 2019, an estimated $23.3M increase.
  • GW&K Investment Management's biggest Q4 2019 reduction was TSMC, cutting an estimated $25.2M.
  • GW&K Investment Management fully exited Cambrex Corporation in Q4 2019, selling an estimated $27.1M.
  • GW&K Investment Management's ten largest holdings make up 12% of its $7.49B portfolio in Q4 2019.
  • GW&K Investment Management opened 15 new positions and closed 9 in Q4 2019.
  • GW&K Investment Management's portfolio value rose 5.4% quarter-over-quarter to $7.49B.

Based on GW&K Investment Management's 13F filing for Q4 2019, filed 10 Feb 2020.